GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

XCell Therapeutics 373110.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

779

-18.34%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About XCell Therapeutics

Its shares trade on KOSDAQ under the ticker 373110.KQ. It has been listed since 15 July 2024. In the fiscal year to 31 December 2025, it reported revenue of ₩1.95bn and a net loss of ₩10.93bn. At that date it held total assets of ₩15.72bn and shareholders' equity of ₩7.14bn.

XCell Therapeutics Inc is a KR-based company operating in Biotechnology industry. The company is headquartered in Seoul, Seoul. The company went IPO on 2024-07-15. Xcell Therapeutics Inc is a provider of biotechnology research and development services. The firm is located in Seoul, South Korea.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
15 Jul 2024
Website
xcell.media ↗

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • XCell Therapeutics Inc operates in Seoul, South Korea, leveraging local biotechnology expertise.
  • The company's IPO on 15 July 2024 provides access to capital for R&D expansion.
  • Seoul's biotechnology ecosystem supports XCell's research and development activities.

Weaknesses

  • XCell Therapeutics Inc's operations are limited to Seoul, South Korea, restricting broader market reach.
  • The company's IPO date of 15 July 2024 indicates a relatively new market presence.
  • Seoul's biotechnology sector faces intense competition from established firms.

Opportunities

  • South Korea's growing biotechnology market offers expansion potential for XCell Therapeutics Inc.
  • The company can leverage Seoul's biotechnology cluster for strategic partnerships.
  • XCell Therapeutics Inc can target international markets through biotechnology collaborations.

Threats

  • Seoul's biotechnology sector is highly competitive, challenging XCell's market position.
  • The company's recent IPO on 15 July 2024 may face volatility in market conditions.
  • South Korea's biotechnology industry faces regulatory challenges affecting innovation.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.